Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Brogan, Anita J ^a   Talbird, Sandra E ^a   Thompson, James R ^a   Miller, Jeffrey D ^a   Rubin, Jaime ^b   Deniz, Baris ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; TELAPREVIR; ALPHA INTERFERON; MACROGOL DERIVATIVE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN;

ADULT; ANEMIA; ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GENOTYPE; HEADACHE; HEPATITIS C; HUMAN; LEUKOPENIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; MULTICENTER STUDY (TOPIC); NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RELAPSE; UNITED STATES; VIROLOGY; CHEMICALLY INDUCED; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG EFFECTS; ECONOMICS; FOLLOW UP; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; STATISTICAL MODEL;

ANEMIA; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MODELS, ECONOMIC; MULTICENTER STUDIES AS TOPIC; OLIGOPEPTIDES; OUTCOME ASSESSMENT (HEALTH CARE); POLYETHYLENE GLYCOLS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84897441948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090295     Document Type: Article

References (58)

1. World Health Organization (WHO) (2011) Hepatitis C. Available: http://www. who.int/mediacentre/factsheets/fs164/en/. Accessed 10 February 2012.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, et al. (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Int Med 144: 705-714. (Pubitemid 46780630)
3. Centers for Disease Control and Prevention (CDC) (2011) Hepatitis C information for health professionals: statistics and surveillance. Available: http://www.cdc.gov/hepatitis/HCV/StatisticsHCV.htm. Accessed 13 February 2012.
4. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW (2010) Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138: 513-521, 521, e1-e6.
5. Thein HH, Yi Q, Dore GJ, Krahn MD (2008) Estimate of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 48: 418-431.
6. But DYK, Lai CL, Yuen MF (2008) Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 14: 1652-1656.
7. Wong JB, McQuillan GM, McHutchison JG, Poynard T (2000) Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 90: 1562-1569.
8. Nainan OV, Alter MJ, Kruszon-Moran D, Gao FX, Xia G, et al. (2006) Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 131: 478-484. (Pubitemid 44142463)
9. McHutchison JG, Bacon BR (2005) Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 11 (10 Suppl): S286-S295. (Pubitemid 41552219)
10. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965. (Pubitemid 32913521)
11. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
12. Cammà C, Cabibbo G, Bronte F, Enea M, Licata A, et al. (2009) Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis. J Hepatol 51: 675-681.
13. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416.
14. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, et al. (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364: 2417-2428.
15. Vertex Pharmaceuticals Incorporated (2012) INCIVEK (telaprevir) film coated tablets [prescribing information]. Cambridge, MA: Vertex Pharmaceuticals Incorporated.
16. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, et al. (2007) Sustained virological response to interferon-a is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45: 579-587. (Pubitemid 46453759)
17. Veldt BJ, Heathcote J, Wedemeyer H, Reichen J, Hofmann WP, et al. (2007) Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Int Med 147: 677-684. (Pubitemid 351664462)
18. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, et al. (2000) Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32: 1131-1137.
19. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
20. Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24: 289-293. (Pubitemid 26260021)
21. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, et al. (1997) Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Int Med 127: 855-865.
22. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ (2010) Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transplantation 16: 748-759.
23. Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, et al. (2006) Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 55: 1332-1338. (Pubitemid 44277366)
24. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, et al. (2010) Liver transplantation in the United States, 1999-2008. Am J Transplant 10 (4 pt2): 1003-1019.
25. National Cancer Institute (NCI) (2009) Fast stats: an interactive tool for access to SEER cancer statistics. Liver and intrahepatic bile duct cancer; complete prevalence. SEER November 2009 submission. Available: http://seer.cancer.gov/faststats. Accessed 24 February 2011.
26. Thein HH, Krahn M, Kaldor JM, Dore GJ (2005) Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol 100: 643-651. (Pubitemid 40487565)
27. Micromedex Redbook Online 2.0 (2013) Available: http://www. micromedexsolutions.com/micromedex2/librarian/. Accessed 1 April 2013.
28. Centers for Medicare and Medicaid Services (2012) Medicare/Medicaid clinical laboratory fee schedule (CMS Lab 2012). Available: https://www.cms.gov/ ClinicalLabFeeSched/. Accessed 19 April 2012.
29. Centers for Medicare and Medicaid Services (2012) Medicare/Medicaid physician fee schedule for 2012 (CMS Phys 2012). Available: https://www.cms.gov/ apps/physician-fee-schedule/. Accessed 19 April 2012.
30. Darbinian JA, Velez FF, Quesenberry CP, Ray GT, Deniz B, et al. (2010) The effect of hepatitis C treatment response on medical costs: a 5-year longitudinal analysis in a managed care setting. Poster presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA. October 30-November 3, 2010. Available: http://www.natap.org/2010/ AASLD/AASLD-60.htm. Accessed 3 August 2011.
31. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, et al. (2011) All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 17: 531-46.
32. US Department of Veterans Affairs (USDVA) (2010) National Hepatitis C Program Office. Clinical manual: interferon and ribavirin treatment side effects. Available: http://www.hepatitis.va.gov/provider/reviews/treatment-side- effects.asp. Accessed 4 April 2013.
33. Wright K, Becker S (2003) Side effect management of hepatitis C treatment. HCV Advocate [online] 6. Available: http://www.hcvadvocate.org/news/ NewsUpdates-pdf/2.4.1-HCV-Advocate-2003/advocate0303.pdf. Accessed 27 December 2010.
34. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, et al. (2002) Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122: 1303-1313. (Pubitemid 34465173)
35. Cammà C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, et al. (2004) Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 39: 333-342. (Pubitemid 38222174)
36. Sherman KE, Sulkowski MS, Zoulim F, Alberti A, Wei LJ, et al. (2011) Follow-up on SVR durability and viral resistance in patients with chronic hepatitis C treated with telaprevir-based regimens: interim analysis of the EXTEND study. Hepatology 54: 485A-486A.
37. Miniño AM, Murphy SL, Xu J, Kochanek KD, Division of Vital Statistics (2011) Deaths: final data for 2008. Table 3. Number of deaths and death rates, by age, race, and sex: United States, 2008. National Vital Statistics Reports 59). Available: http://www.cdc.gov/nchs. Accessed 19 April 2012.
38. US Bureau of Labor Statistics (BLS) (2012) Consumer Price Index-all urban consumers; medical care. Series ID: CUUR0000SAM (not seasonally adjusted) [value for 2012 selected from June 2012]. Available: http://data.bls.gov/cgi- bin/surveymost?cu. Accessed 14 September 2012.
39. The EuroQol Group (1990) EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16: 199-208.
40. Younossi Z, Aggarwal J, Martin M, Hernandez N, Donepudi M, et al. (2012) Health-related quality-of-life among genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment: post-hoc analyses of data from the advance trial. J Hepatol 56: S462-S463.
41. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. New York: Oxford University Press.
42. Thein HH, Yi Q, Heathcote EJ, Krahn MD (2009) Prognosis of hepatitis C virus-infected Canadian post-transfusion compensation claimant cohort. J Viral Hepat 16: 802-813.
43. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS (2008) What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 46: 349-356.
44. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ (2003) Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 290: 228-237. (Pubitemid 37430062)
45. Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD (2011) Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS One 6: e26783.
46. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V (2011) Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 45: e17-24.
47. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, et al. (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices- Modeling Studies. Value Health 6: 9-17. (Pubitemid 36228345)
48. Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, et al. (2004) Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 99: 1490-1496. (Pubitemid 39180097)
49. Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK, et al. (2003) Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol 98: 2354-2362. (Pubitemid 37448742)
50. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD (2012) New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Int Med 156: 279-290.
51. Hornberger J, Torriani FJ, Dieterich DT, Bräu N, Sulkowski MS, et al. (2006) Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J Clin Virol 36: 283-291. (Pubitemid 44066896)
52. Spackman DE, Veenstra DL (2008) A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 26: 937-949.
53. Brogan A, Mauskopf J, Talbird SE, Smets E (2010) US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment experienced, HIV infected adults with evidence of protease inhibitor resistance included in the TITAN trial. Pharmacoeconomics 28 (suppl 1): 129-146.
54. Sax PE, Losina E, Weinstein MC, Paltiel AD, Goldie SJ, et al. (2005) Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr 39: 69-77. (Pubitemid 40617021)
55. Townsend R, McEwan P, Kim R, Yuan Y (2011) Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health 14: 1068-1077.
56. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, et al. (1997) Morbidity and mortality in compensated cirrhosis type C: a retrospective followup study of 384 patients. Gastroenterology 112: 463-472. (Pubitemid 27078833)
57. Brogan AJ, Talbird SE, Thompson JR, Miller JD, George S, et al. (2012) Cost-effectiveness of first-line versus second-line telaprevir combination treatment in the management of chronic hepatitis C virus infection for treatment-naïve patients with IL28B genotype CC. Podium presentation at Digestive Disease Week; May 19-22. San Diego, CA.
58. Druyts E, Thorlund K, Humphreys S, Lion M, Cooper CL, et al. (2013) Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection. Clin Epidemiol 5: 173-183.